FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.

More than half of those sickened are young children, and 8 people have been hospitalized.

Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Results for weight loss treatment combo cagrilintide and semaglutide; positive results for treatment of rare form of ALS, and for sefaxersen in adults with primary IgA nephropathy; gene therapy approv...

Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.

Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.

Survey finds similar pattern for families avoiding applying for government programs and sending their kids to school due to immigration concerns.

Investigational combination therapy CagriSema demonstrated significant weight reduction and noninferior HbA1c lowering in phase 3 clinical trials.

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib i...

Courts are limiting the "error in judgment" defense: why diagnostic missteps do not qualify as acceptable clinical decision-making under the law.

A single IV infusion of the AAV9 gene therapy demonstrated statistically significant cognitive improvements compared with natural history controls in young children with preserved neurodevelopmental f...

Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib i...

Phase 3 CELESTIMO study demonstrates significant progression free survival benefit for an mosunetuzumab combination regimen in relapsed or refractory follicular lymphoma.

All participating US comprehensive cancer centers report a shortage of at least 1 drug with 20% reporting 5 or more medications in short supply.

Phase 3 Emerge trial results show a single 100µg dose of lysergide ODT produced rapid, statistically significant, and durable improvements in depression scores through 12 weeks.

Likelihood of filling additional prescriptions increased with prescription supply length up to seven years after index fill

Phase 3 HAELO data showed an 87% reduction in monthly attack rates with Ionvoguran ziclumeran, with a PDUFA target date of March 10, 2027.

Accelerated approval of Etcamah combined with a CDK4/6 inhibitor provides a ctDNA-guided therapy switch for patients with ESR1-mutated, HR+/HER2- advanced breast cancer prior to clinical disease progr...

Mounjaro approval expanded to reduce the risk of major cardiovascular events; The American Academy of Pediatrics has issued updated recommendations for RSV immunization; BTK inhibitor shows promise in...

A closer look at five anticipated FDA approval decisions in October 2026 spanning oncology, infectious diseases, and ophthalmology.

The updated guidelines broaden the high-risk criteria for children aged 8 to 19 months entering their second RSV season.

Drug Pharmacologic class Indication More information Cardiovascular Disease Mounjaro (tirzepatide) Dual glucose-dependent insulinotropic polypeptide

Mimrylo is the first subcutaneous hepcidin mimetic approved to control hematocrit levels and reduce phlebotomy burden in patients with polycythemia vera.

However, at 24 months, Mediterranean-style diet yielded higher diet quality.

The FDA expanded tirzepatide's indication to include major adverse cardiovascular event reduction in adults with type 2 diabetes and established CV risk.

A daily single-tablet combination of bictegravir and lenacapavir offers a simplified treatment option for virologically suppressed adults with HIV-1.

A daily single-tablet combination of bictegravir and lenacapavir offers a simplified treatment option for virologically suppressed adults with HIV-1.

Associations not seen in population-based analyses; null effects persisted in sibling-comparison analysis.

Lisraya is the first oral dual TYK2/JAK1 inhibitor indicated for adults with dermatomyositis, demonstrating significant disease activity improvement and corticosteroid reduction.

The FDA expanded tirzepatide's indication to include major adverse cardiovascular event reduction in adults with type 2 diabetes and established CV risk.

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with chemotherapy in metastatic PDAC.

Phase 3 CROSSING trial data show tezepelumab significantly improved histologic remission and dysphagia in patients aged 12 and older with eosinophilic esophagitis.

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with chemotherapy in metastatic PDAC.

The first-of-its-kind dual continuous sensor tracks real-time glucose and background ketone trends to help prevent diabetic ketoacidosis in patients taking insulin or glucose-lowering therapy.

MPR speaks to Dr William Schaffner of Vanderbilt University about vaccines and the rollout of the mFlusiva vaccine.

The FDA requires an additional 3 months to review a major amendment to the Biologics License Application for deramiocel, moving the PDUFA target date to November 22, 2026.

One phlebotomist can oversee up to 3 Aletta machines, directly helping to address the current phlebotomist shortage and long wait times.

MPR speaks to Dr William Schaffner of Vanderbilt University about vaccines and the rollout of the mFlusiva vaccine.

Intismeran autogene is a personalized mRNA therapy that targets a tumor's unique mutational signature to trigger an anticancer immune response.

The selective D1 receptor antagonist reduced tic severity and relapse risk in clinical trials, with a regulatory action date set for Q1 2027.

While study did not reveal a causal link, authors advise reducing exposure, particularly to products with fragrances.

The approval was supported by data from the phase 3 OPTIMA trial, which enrolled 63 adults with FOP confirmed by an ACVR1 FOP-causing mutation.

Intismeran autogene is a personalized mRNA therapy that targets a tumor's unique mutational signature to trigger an anticancer immune response.

MPR speaks to Dr William Schaffner of Vanderbilt University about vaccines and the rollout of the mFlusiva vaccine.

Florquinitau F 18 is a radioactive diagnostic agent that binds to aggregated tau protein.

Accelerated FDA approval of the first-in-class CELMoD agent iberdomide (Zenbexus) offers a new oral option for adults with relapsed or refractory multiple myeloma.

A medical malpractice case study demonstrates how accurate documentation of clinical decline without physician intervention led to an $8 million verdict.